Estrogen is a robust stimulator of galanin synthesis and secretion in the anterior pituitary. Galanin is colocalized in lactotrophs in the estrogen-treated anterior pituitary, and its roles in lactotroph function are still being elucidated. In the present studies, we quantified the phenotypes of estrogen-treated Fischer 344 rat anterior pituitary cells expressing the galanin gene by dual in situ hybridization. The total population of galanin-positive pituitary cells increased from undetectable levels to 16% of all cells after 2 weeks of estrogen treatment. More than 90% of the galanin-positive cells coexpressed PRL messenger RNA, and one-third of the lactotrophs expressed galanin messenger RNA. We hypothesized that galanin in the anterior pituitary may contribute to the heterogeneous secretion of PRL, and that one of the functions of galanin is to regulate PRL secretion in an autocrine/paracrine manner. To test this hypothesis, we performed the reverse hemolytic plaque assay combined with in situ hybridization to measure PRL secretion and galanin gene expression within the same individual cells. PRL secretion from galanin-positive lactotrophs was significantly greater than that from galanin-negative lactotrophs. Moreover, treatment with galanin antiserum significantly attenuated PRL secretion from galanin-positive cells, and treatment with galanin significantly enhanced PRL secretion from galanin-negative lactotrophs. In conclusion, these data provide direct evidence that galanin derived from the estrogen-treated anterior pituitary stimulates PRL secretion in both autocrine and paracrine manners. (Endocrinology 139: [2452][2453][2454][2455][2456][2457][2458] 1998) G ALANIN was originally isolated from the porcine intestine in 1983 (1). Since then, galanin has been localized to remarkably diverse areas throughout the central and peripheral nervous systems (2, 3). Numerous studies have indicated that galanin is a hypothalamic-hypophysiotrophic hormone (4, 5). Indeed, the highest concentration of galanin peptide in the nervous system is located in hypothalamic neurons (6). During the past several years, the studies of this laboratory have concentrated on the regulation of galanin synthesis and secretion in a nonneuronal tissue, the anterior pituitary gland (7-10). Estrogen is, thus far, the most potent stimulus of galanin synthesis and secretion in the anterior pituitary (11). Estrogen increases galanin messenger RNA (mRNA) levels more than 100-fold, and increases galanin peptide content more than 50-fold in the anterior pituitary (11). We and others showed that estrogen treatment dramatically increases the number of galanin cells as determined by immunocytochemistry (10, 12) and that this effect is, at least in part, due to the direct effects of estrogen at the level of the pituitary. Using immunocytochemistry, galanin peptide in the anterior pituitary has been localized in lactotrophs, somatotrophs, and thyrotrophs in female rats, whereas only somatotrophs and thyrotrophs in male rats contain galanin peptide (13). In intact female rats, the majority of galanin peptide appears to be located in lactotrophs (13), but no studies have quantified the number of lactotrophs capable of synthesizing galanin, especially at the level of gene expression.
G ALANIN was originally isolated from the porcine intestine in 1983 (1). Since then, galanin has been localized to remarkably diverse areas throughout the central and peripheral nervous systems (2, 3) . Numerous studies have indicated that galanin is a hypothalamic-hypophysiotrophic hormone (4, 5) . Indeed, the highest concentration of galanin peptide in the nervous system is located in hypothalamic neurons (6) . During the past several years, the studies of this laboratory have concentrated on the regulation of galanin synthesis and secretion in a nonneuronal tissue, the anterior pituitary gland (7) (8) (9) (10) . Estrogen is, thus far, the most potent stimulus of galanin synthesis and secretion in the anterior pituitary (11) . Estrogen increases galanin messenger RNA (mRNA) levels more than 100-fold, and increases galanin peptide content more than 50-fold in the anterior pituitary (11) . We and others showed that estrogen treatment dramatically increases the number of galanin cells as determined by immunocytochemistry (10, 12) and that this effect is, at least in part, due to the direct effects of estrogen at the level of the pituitary. Using immunocytochemistry, galanin peptide in the anterior pituitary has been localized in lactotrophs, somatotrophs, and thyrotrophs in female rats, whereas only somatotrophs and thyrotrophs in male rats contain galanin peptide (13) . In intact female rats, the majority of galanin peptide appears to be located in lactotrophs (13) , but no studies have quantified the number of lactotrophs capable of synthesizing galanin, especially at the level of gene expression.
The regulation of pituitary galanin synthesis and secretion parallels that of PRL in many regards. PRL is one of the best studied anterior pituitary hormones (14) , and much is known about the factors regulating its gene expression and secretion. Estrogen dramatically increases PRL synthesis and secretion (15) . PRL is secreted in a very heterogeneous pattern, which does not correlate with PRL gene expression at the level of the single cell (16, 17) . Fischer 344 rats develop a dramatic pituitary hyperplasia after 2 weeks of estrogen treatment, and more prolonged estrogen treatment can induce hyperprolactinemia and prolactinomas (18) . We reported that estrogen stimulates a similar pattern of secretion of galanin and PRL in vitro (10) , and that galanin and PRL peptides are located within the same secretory granules in lactotrophs of estrogen-treated rats (19) . Moreover, receptor binding studies indicate that there are high affinity galanin receptors in the pituitary (20) , and a recently cloned galanin receptor (GALR2) is expressed in the rat anterior pituitary (21) . Therefore, we hypothesized that the function of pituitary galanin is to regulate the secretion of PRL in an autocrine and/or paracrine manner.
To test our hypothesis and to better understand the function of galanin in the anterior pituitary, we performed the following experiments. First, we quantified the precise distribution of the population of galanin-positive cells in the anterior pituitary by colocalizing galanin mRNA with PRL and GH mRNAs by using dual in situ hybridization. Second, we compared PRL secretion in both galanin-positive and galanin-negative lactotrophs at the level of the individual cell by using the reverse hemolytic plaque assay combined with in situ hybridization. Finally, we examined whether galanin exerts autocrine and/or paracrine effects on PRL secretion by blocking the access of galanin to galanin-positive lactotrophs with a specific galanin antiserum, and treating galanin-negative lactotrophs with synthetic galanin.
Materials and Methods Animals
Female Fischer 344 rats (6 -7 weeks old, National Cancer Institute) were housed in a 14-h light, 10-h dark environment (lights on at 0700 h) and provided laboratory chow and water ad libitum. Animals were bilaterally ovariectomized using Brevital anesthesia (50 mg/kg BW; Eli Lily & Co., Indianapolis, IN), and some of the animals were implanted sc with a 2-mm SILASTIC brand capsule (Dow Corning, Midland, MI) containing crystalline 17␤-estradiol as previously described (19) . Two weeks later, animals were decapitated (0900 -1100 h) after anesthesia with Brevital. The pituitaries were rapidly removed and used for the following three experiments. All experimental procedures were conducted in accordance with the policies of the University of Kentucky Institutional Animal Care and Use Committee.
Experimental design
Exp 1. Pituitaries from ovariectomized (n ϭ 3) and ovariectomized estrogen-treated (n ϭ 3) rats were frozen on dry ice, and then sectioned (7.5 m) on a cryostat. Three representative sections from each pituitary were used to perform in situ hybridization to measure the effects of estrogen on galanin gene expression.
Exp 2.
To quantify the galanin-positive cell population in the anterior pituitary, dual in situ hybridization was performed using dispersed anterior pituitary cells from estrogen-treated rats. Anterior pituitaries (n ϭ 3; 4 slides per animal) were carefully dissected from the neural and intermediate lobes. Cells were dispersed using a standard trypsin treatment as previously described (10) . Briefly, pituitary fragments were incubated at 37 C with trypsin (0.2%) for 30 min, DNase I (0.1%) for 2 min, and then rinsed with lima bean trypsin inhibitor (0.075%) twice. Cell counts were performed using a hemocytometer. Approximately 50,000 cells were placed onto microscope slides freshly coated with poly-l-lysine (200 g/ml; Sigma Chemical Co., St. Louis, MO). Cells were allowed to attach to the microscope slides for 30 min at room temperature, and then fixed in phosphate-buffered 4% paraformaldehyde. Dual in situ hybridization histochemistry was performed on these slides with 35 S-UTP (galanin) and digoxigenin-UTP labeled (PRL and GH) complementary RNAs (cRNAs).
Exp 3. The reverse hemolytic plaque assay (22) combined with in situ hybridization was performed in this study to measure PRL secretion and galanin gene expression at the level of the individual cell (n ϭ 3 animals, 3 slides per animal). Conjugation of protein A (Sigma) with ovine red blood cells (oRBC; CO Serum Co., Denver, CO), was performed 24 h before the assay (23) . The next day, dispersed anterior pituitary cells were obtained from estrogen-treated rats as described in Exp 2. Protein A-coated oRBCs and monodispersed anterior pituitary cells [20% oRBCs, 4 ϫ 10 4 /ml anterior pituitary cells in DMEM/0.1% BSA (Sigma)] were incubated in a Cunningham chamber with different treatments: medium alone, normal rabbit serum (1:25), galanin antiserum (1:100 and 1:25) (24) or synthetic rat galanin (1 m; Peninsula Laboratories, Inc., Belmont, CA). The antiserum used in the present study was obtained from the fifth bleeding of rabbit JFH2319. No significant molar crossreactivity with rat GH, rat PRL, rat LH, ACTH, rat GHRH, TRH, LHRH, somatostain-14, rat CRH, arginine vasopressin, oxytocin, bradykinin, VIP, angiotensin II, or human galanin was observed. The antiserum appears to recognize the carboxy-terminus of the rat galanin peptide due to the fact that the first 15 amino acids of rat and human galanin are identical, and this antiserum failed to recognize human galanin. The immunoglobulins in the normal rabbit serum and galanin antiserum were purified by ammonium sulfate precipitation, followed by extensive dialysis in borate-buffered saline (25) . After a 45-min incubation, all chambers were washed with DMEM/0.1% BSA, and then treated with a rPRL antibody (26) (1:70, provided by Dr. N. Ben-Jonathan) combined with the treatment solution for one additional hour. After washing the cells, a guinea pig complement solution (1:60, Life Technologies, Gaithersburg, MD) was added to the chamber and incubated for 50 min. All incubations were performed at 37 C in a water-saturated CO 2 incubator (5%CO 2 /95% air). The slides were then fixed in 4% paraformaldehyde for in situ hybridization of galanin mRNA.
Complementary DNA (cDNA) templates and cRNA probe preparation
A 585-bp rat galanin cDNA was generated in our laboratory by RT-PCR using total RNA from an estrogen-treated rat anterior pituitary. This cDNA (ϩ110 to ϩ695) corresponds to a part of the coding region of galanin mRNA (27) and was ligated into pGEM2 (Promega, Madison, WI). The PCR product was verified by dideoxy chain termination sequencing (Sequenase, v2.0, USB Corp., Cleveland, OH). The template was linearized with AvaI and transcribed with T7 RNA polymerase to obtain a 486-bp antisense galanin cRNA. To obtain a sense galanin cRNA, this same template was linearized with HindIII and transcribed with SP6 RNA polymerase. Rat GH and PRL cDNAs were generous gifts from Drs. J. D. Baxter and R. A. Maurer, respectively. The original GH cDNA insert was digested with KpnI and PstI and subcloned into pGEM3Zf(-) (Promega, Madison, WI). The GH template was then linearized with PstI and transcribed with T7 RNA polymerase to produce a 380-bp cRNA probe. The PRL template was linearized with ApalI and transcribed with SP6 RNA polymerase to produce a 430-bp cRNA. A total of 50 mm UTP and 500 mm ATP, CTP, and GTP were used in the following transcription reactions. In Exp 1, the galanin cRNA was transcribed with 7.5 mm 35 S-labeled UTP and 42.5 mm unlabeled UTP, and purified through a G-50 Quick Spin Column (Boehringer Mannheim, Indianapolis, IN), which yielded an antisense cRNA with a specific activity of 3.4 ϫ 10 8 dpm/g RNA. Sense galanin cRNA was transcribed in a similar manner and yielded a comparable specific activity. In Exp 2, the galanin cRNA was transcribed with 30 mm 35 S-labeled UTP and 20 mm unlabeled UTP to yield a probe with a much higher specific activity (1.3 ϫ 10 9 dpm/g RNA). GH and PRL cRNAs were transcribed with 30 mm digoxigenin-labeled UTP and 20 mm unlabeled UTP. In Exp 3, the galanin cRNA was transcribed as described in Exp 2.
In situ hybridization, dual in situ hybridization, in situ hybridization combined with the reverse hemolytic plaque assay
In situ hybridization histochemistry was performed according to the method of Cai and Wise (28) . The tissues were fixed in 4% paraformaldehyde for different lengths of time in individual experiments. In Exp 1, pituitary sections were fixed for only 5 min, whereas in Exp 2, dispersed pituitary cells were maintained in the paraformaldehyde solution overnight. In Exp 3, after the reverse hemolytic plaque assay, slides were immersed in 4% paraformaldehyde for up to 2 days. The slides were then sequentially washed in 0.1 m phosphate buffer, diethylpyrocarbonatetreated water, acetic anhydride (0.25%) diluted in 80 mm (pH 8.0) triethanolamine buffer and 2 ϫ SSC (1 ϫ SSC ϭ 0.15 m NaCl, 0.015 m sodium citrate). Hybridization buffer (25 l, Amresco, Solon, OH) containing 0.3 g/ml cRNA of galanin was applied to each slide. For dual in situ hybridization, the radiolabeled galanin cRNA was added together with either GH or PRL cRNAs. The slides were coverslipped and incubated overnight (16 h) at 55 C in a humidified incubator. After hybridization, the coverslips were removed in 4 ϫ SSC. The slides were then treated with RNase A (20 g/ml) at 37 C for 30 min, washed in RNase buffer at 37 C for 30 min, followed by two washes in 0.2 ϫ SSC at room temperature for 15 min each and 0.1 ϫ SSC at 60 C for 1 h. The slides were briefly dehydrated in 70% alcohol for 10 sec and then air dried. The slides from Exp 1 and 3 were then dipped in 1:1 diluted Kodak NTB-2 emulsion (Eastman Kodak, Rochester, NY) and exposed for 4 days and 1 week, respectively, to visualize the hybridized signals.
The detection of the signals from the digoxigenin-labeled PRL and GH cRNAs in Exp 2 was performed according to the method of Eyigor and Jennes with modifications (29) . After preincubation (4% lamb serum, 0.2% Triton-X-100 in 2 ϫ SSC), the slides were rinsed in freshly prepared buffer A (100 mm Tris pH 7.5, 150 mm NaCl), and incubated with antidigoxigenin (Boehringer Mannheim, Indianapolis, IN) solution (1:1000 anti-digoxigenin, 5% lamb serum, 0.3% Triton-X-100 in buffer A) overnight. Digoxigenin signals were detected the following morning in a dark environment. Signals for both GH and PRL mRNAs could be detected after a 30-min incubation in chromagen solution, which consisted of 35 l X-phosphate and 45 l NBT (Boehringer Mannheim, Indianapolis, IN) in freshly prepared buffer B (100 mm Tris, pH 9.5, 100 mm NaCl, 50 mm MgCl 2 ). Eosin counterstain was used to visualize all of the cells. The slides were then briefly dehydrated in 70% alcohol for 10 sec, air dried, and dipped in 1:1 diluted Ilford emulsion (Polysciences, Inc., Warrington, PA), and exposed for 1 week to visualize the signals for galanin mRNA. The percentage of the galanin-positive cells in the dispersed anterior pituitary cells using single-labeled in situ hybridization was identical to that in dual in situ hybridization (data not shown).
Image and data analysis
In Exp 2, the numbers of total cells, lactotrophs, galanin-positive cells, and cells coexpressing galanin/PRL were counted on the same slides probed with galanin and PRL cRNAs. Numbers of total cells, somatotrophs, galanin-positive cells, and cells coexpressing galanin/GH were counted on the same slides probed with galanin and GH cRNAs. Cells were counted from at least 20 different representative areas (totaling approximately 2000 cells) on each slide, the mean number of the total counts was used to represent the animal (4 slides per animal). Data are presented as means Ϯ se (n ϭ 3) of the percentage of specific cell types in the anterior pituitary cell population.
In Exp 3, the areas of PRL-secreting plaques were measured using an image analysis system (BioQuant OS/2; R&M Biometrics, Nashville, TN) (28) 
Results

Exp 1
To confirm the induction of galanin gene expression by estrogen in the anterior pituitary at the cellular level, and to validate our galanin cRNA probe, we performed in situ hybridization to measure galanin mRNA levels in the anterior pituitaries of ovariectomized and ovariectomized estrogentreated rats. There was no detectable galanin mRNA signal in the ovariectomized anterior pituitary (Fig. 1A) . Estrogen treatment dramatically increased galanin gene expression in the anterior pituitary, and no signals were detected in the posterior pituitary (neural or intermediate lobes; Fig. 1B ). In addition, no signal was observed using a sense galanin cRNA (Fig. 1C) , confirming the specificity of the galanin antisense cRNA probe. As illustrated in Fig. 1 , the cells are extremely compacted within the rat anterior pituitary gland, and it is not possible to reliably or accurately distinguish and quantify single radiolabeled cells. Therefore, we performed dual in situ hybridization in Exp 2 using dispersed anterior pituitary cells. Because we could not detect any signal for galanin mRNA in ovariectomized rats, we performed the following experiments in ovariectomized estrogen-treated rats only.
Exp 2
To obtain precise quantitative information regarding the galanin cell population in the anterior pituitary of estrogentreated animals, we performed dual in situ hybridization using a galanin cRNA with either PRL or GH cRNA probes (Figs. 2 and 3) . Figure 2 shows representative photomicrographs of the dual in situ hybridization results using the galanin and PRL cRNAs. The distribution of the three different cell types (galanin-, PRL-, and GH-positive cells) in the anterior pituitary and their relationships are shown in Fig. 3 . The percentages of somatotrophs, galanin-positive cells and lactotrophs in the total population of estrogen-treated ante-FIG. 1. Representative dark-field photomicrographs of galanin mRNA in the anterior pituitaries of ovariectomized (A) and ovariectomized estrogen-treated rats (B and C) using in situ hybridization. The pituitary sections in panels A and B were labeled with a galanin antisense cRNA probe, and the pituitary section in panel C was labeled with a galanin sense cRNA probe with the same specific activity.
rior pituitary cells were 13.5%, 16%, and 51%, respectively. Fifteen percent of the total number of cells coexpressed galanin and PRL mRNAs, whereas only 0.3% of the total cell population coexpressed galanin and GH mRNAs. One-third of all lactotrophs expressed galanin mRNA. More than 93% of the galanin-positive cells were lactotrophs, and less than 2% of the galanin-positive cells were somatotrophs in estrogen-treated Fischer 344 female rats.
Exp 3
Because the majority of galanin-positive cells are lactotrophs, we designed the following study to elucidate whether galanin in lactotrophs regulates PRL secretion from the anterior pituitary, and if so, whether galanin regulates PRL secretion in an autocrine and/or paracrine manner. We performed the reverse hemolytic plaque assay combined with in situ hybridization to measure PRL secretion and galanin gene expression in the same individual cells (Figs. 4  and 5 ). Figure 4 shows representative photomicrographs of PRL-secreting cells using the reverse hemolytic plaque assay combined with in situ hybridization. PRL secretion from single cells was measured in all treatments. For the purpose of analysis, the plaque areas from each treatment were divided into two groups based upon the detection of galanin mRNA: galanin-positive and galanin-negative lactotrophs. Two-way ANOVA revealed a significant interaction between treatment [medium alone, normal rabbit serum (1:25), galanin antiserum (1:100 and 1:25) and galanin (1 m)] and group (galanin-positive and galanin-negative lactotrophs) (P Ͻ 0.005). The galanin-positive lactotrophs in medium alone, as well as after normal rabbit serum treatment, had significantly larger plaque areas as compared with those of galanin-negative lactotrophs (P Ͻ 0.05) (Figs. 4 and 5 ). When we compared the plaque areas among different treatments in the group of galanin-positive lactotrophs, we detected significantly smaller plaque areas using both concentrations of galanin antiserum, and no differences using normal rabbit serum and galanin treatment compared with medium alone (Fig. 5) . When we compared the plaque areas among different treatments in the group of galanin-negative lactotrophs, we detected significantly larger plaques areas after galanin treatment, and no differences after normal rabbit serum and different concentrations of galanin antiserum treatment compared with medium alone (Fig. 5) . Regression analysis revealed no correlation between PRL secretion (plaque area) and galanin gene expression (video count area of grains) (r ϭ Ϫ0.1776; P Ͻ 0.20, n ϭ 82 cells).
Discussion
Many biologically active, low molecular weight peptides have been isolated from neurons in both the peripheral and central nervous systems. Many of these neuropeptides are believed to serve a modulatory role in neurotransmission. However, the functions of some of these peptides in nonneuronal tissues, such as the epithelial cells of the anterior pituitary gland, have been far less studied principally due to their low levels of expression. In this regard, galanin serves a somewhat unique role in that its expression in the anterior pituitary gland is markedly increased by estrogen (10, 11) , thus allowing for precise quantitative measurements and experimental manipulations to identify some of its physiological functions.
Our present study provides direct evidence for an autocrine and paracrine function for galanin in regulating PRL secretion. The dramatic increase of the levels of galanin mRNA in the anterior pituitary gland by estrogen is not only due to an increase in the number of galanin-expressing cells, as previously shown by immunocytochemistry (10, 12) , but is also the result of increasing the level of galanin gene expression within each cell. No galanin mRNA was detected in either the neural or intermediate lobes of the pituitary, although immunoreactive galanin peptide is present in the axon terminals of the neural lobe (30; unpublished observation). The present study is the first to quantify the subpopulation of galanin-expressing cells. In estrogen-treated female rats, more than 93% of galanin-positive cells are lactotrophs. This large degree of colocalization with PRL strongly supports our hypothesis that one of the functions of pituitary galanin is to regulate the secretion of PRL. The small degree of colocalization of galanin and GH mRNAs suggests that galanin may not exert a major function in regulating GH in the estrogen-treated anterior pituitary. Nevertheless, a small subpopulation of somatotrophs appears to be sensitive to estrogen, as determined by the induction of the galanin gene.
It is tempting to speculate that this population of somatotrophs may, in fact, be mammosomatotrophs. However, triple-labeling experiments will be needed to prove this possibility. The present study is also the first to compare PRL secretion between galanin-positive and galanin-negative lactotrophs at the level of individual cell. Neill and Frawley showed previously that the amount of PRL secreted from a lactotroph correlates with the size of the plaque in the reverse hemolytic plaque assay (23, 31) . That is, lactotrophs secreting more PRL have larger plaque areas, and therefore the plaque area and PRL secretion are directly correlated. Galanin-positive lactotrophs secrete significantly greater amounts of PRL as compared with galanin-negative lactotrophs. Therefore, by increasing PRL secretion at the level of individual cell, galanin may mediate, at least in part, the estrogen-induced stimulation of PRL secretion. Because galanin is only contained in one-third of the lactotrophs, we believe that galanin in the anterior pituitary may also contribute to the heterogeneous secretion pattern of PRL.
Data from the plaque assay shed light on the cellular and molecular mechanisms of galanin-mediated PRL secretion. Our previous studies showed that galanin and PRL are located in the same secretory granules and are released simultaneously (19) . We hypothesized that galanin stimulated PRL secretion in an autocrine and/or paracrine manner. By placing the pituitary cells far apart from one another in the plaque assay, we severely diminished the opportunity for galanin secreted from one cell to reach adjacent cells. Therefore, we predicted that galanin secreted from a PRL-releasing cell, if acting as a stimulatory autocrine factor, should exert its effects on that cell, i.e. increasing the size of the plaque. Our data support this hypothesis, in that those lactotrophs expressing galanin secrete more PRL than those lactotrophs that do not contain galanin mRNA. To prove that galanin is regulating PRL secretion in an autocrine manner, we blocked the availability of endogenous galanin to the cells by immunoneutralization. Galanin antiserum caused a significant attenuation of PRL secretion from galanin-positive lactotrophs, FIG. 5 . Autocrine and paracrine regulation of PRL secretion by galanin. The mean plaque areas from each treatment and group were used for statistical analysis (mean Ϯ SE, n ϭ 3). Two-way ANOVA revealed a significant interaction between groups (galanin-negative and galanin-positive PRL-secreting cells) and treatment [medium alone as control (C), normal rabbit serum (NRS), galanin antiserum (Anti-GAL; 1:100 and 1:25 dilutions) and galanin (GAL; 1 M)] (P Ͻ 0.005). Multiple comparisons were performed, and P Ͻ 0.05 was considered significant. *, Significant differences when compared with the control galanin-negative group; **, significant differences when compared with the control galanin-positive group. and the levels of PRL secretion were lowered to levels similar to those in galanin-negative lactotrophs. The failure of the galanin antiserum to alter PRL secretion from galaninnegative lactotrophs argues against any nonspecific effects of the antiserum on hormone secretion. In addition, we did not see a further increase of PRL secretion from galanin-positive lactotrophs after galanin treatment. This may be due to the high extracellular concentrations of endogenous galanin surrounding the galanin-positive lactotrophs after estrogentreatment, and a further increase in the galanin concentration by the addition of exogenous galanin is not capable of increasing PRL secretion (i.e. the functional galanin receptors are completely occupied).
We also tested the hypothesis that galanin regulates PRL secretion in a paracrine manner by using in vitro treatment with synthetic galanin. Others have shown that the addition of synthetic galanin is capable of stimulating PRL secretion from rat pituitary cells in vitro (20, 32) . The paracrine regulation of PRL secretion by galanin was also suggested by Wynick et al. using an immunoblot assay (32) . By maintaining a large distance between the pituitary cells in the Cunningham chambers, we are doubtful that galanin secreted from a galanin-positive lactotroph reached neighboring cells. Therefore, if galanin is capable of acting as a paracrine factor to stimulate PRL secretion, exogenous galanin treatment should exert a stimulatory effect on PRL secretion from galanin-negative lactotrophs, i.e. increasing the size of the plaque. Indeed, exogenous galanin increased the PRL plaque area by approximately 50% from galanin-negative cells. It is also important to consider that treatment with the galanin antiserum did not significantly alter the sizes of the plaques from galanin-negative lactotrophs, suggesting that either 1) these cells were not exposed to endogenous galanin; or 2) that these lactotrophs were exposed to endogenous galanin, but that the peptide had no effect on PRL secretion from this subpopulation of PRL-secreting cells. The former possibility is upheld because treatment with galanin significantly increased PRL secretion from galanin-negative lactotrophs. To relate these findings to the whole animal, we infer that PRL secretion from lactotrophs not producing galanin (or producing undetectable levels of galanin mRNA) may be stimulated by endogenous galanin received from either adjacent galanin-positive pituitary cells or from hypothalamic neurons.
In light of previous data, it is not surprising that steadystate galanin gene expression does not correlate with PRL secretion at the level of the individual cell. Scarbrough et al. (16) showed previously that PRL gene expression does not correlate with PRL secretion at the level of the individual cell in ovariectomized and ovariectomized estrogen-treated Sprague-Dawley rats using the reverse hemolytic plaque assay, and Castañ o et al. (17) showed that PRL gene transcription failed to correlate with hormone secretion in lactating rats. We and others showed that estrogen induced the synthesis and secretion of both galanin and PRL with similar time courses (10, 11) . However, it appears that not only are PRL gene expression and secretion independent events, but that the absolute levels of galanin gene expression are also unrelated to PRL secretion. These data suggest that global gene expression per se in the lactotroph may be tightly regulated during specific times within individual cells but that overall gene expression is not coincident with secretion, nor is it strongly coupled to active secretory function.
Galanin in the anterior pituitary may play an intermediate role, via autocrine/paracrine mechanisms, in the formation of estrogen-induced lactotroph hyperplasia and tumorigenesis. Recent studies indicate that autocrine and paracrine factors play important roles in the genesis of some tumors (33, 34) . Galanin stimulates cell proliferation in small cell lung cancer cells (33) and 235-1 cells, a rat pituitary tumor cell line (32) . After 2 weeks of estrogen treatment, Fischer 344 rats develop a dramatic pituitary hyperplasia, and more prolonged estrogen treatment can induce hyperprolactinemia and prolactinomas (18) . We previously showed that bromocriptine and the somatostatin analog SMS 201-995 inhibit galanin gene expression and galanin secretion, and also inhibit estrogen-induced prolactinoma formation (8, 9) . Moreover, pituitary somatotroph adenomas are also associated with increased galanin gene expression and peptide production (35) . Therefore, pituitary galanin may mediate the formation of pituitary hyperplasia and adenomas, not only in estrogen-induced models but also in estrogen-independent models. However, galanin may also subserve a variety of other functions in the pituitary such as interacting with endogenous growth factors or membrane receptors and their second messenger signaling cascades. The recent development of mice with a targeted disruption of the galanin gene (36) , and transgenic mice overexpressing galanin in somatotrophs (37) and lactotrophs (Cai and Hyde, manuscript in preparation) will undoubtedly assist in our understanding of the diverse roles of galanin in pituitary function.
In summary, estrogen upregulates galanin gene expression by increasing both the number of galanin-positive cells and the levels of gene expression. Galanin-positive cells in the estrogen-treated anterior pituitary are mainly lactotrophs. One of the functions of pituitary galanin is to stimulate PRL secretion by acting as an autocrine and paracrine factor.
